Astellas Expands Its Presence In Urology With Myrbetriq Approval
Astellas is tasked with introducing a new product into the already crowded overactive bladder market now that it has gained approval for the beta-3 antagonist mirabegron in the U.S.
Astellas is tasked with introducing a new product into the already crowded overactive bladder market now that it has gained approval for the beta-3 antagonist mirabegron in the U.S.